Autoimmune disorders are treated by the administration of human interferon, particularly IFN-α or IFN-β, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's ...

Hyperallergenic conditions are treated by the administration of interferon at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and pharyngeal mucosae. ...

Neoplastic disease, hyperallergenicity, autoimmune disorders characterized by chronic tissue degenerative inflammation and immuno-resistant viral infections are treated by the administration of interferon at a dosage of ...

Improved methods for administering an interferon (IFN) to a warm-blooded vertebrate are described. The methods employ oral administration of the IFN to the vertebrate in very low dosages, for example, 0.1 to 1.5 IU per ...

Neoplastic diseases are treated by the administration of human interferon, particularly IFN-α, at a dosage of from about 0.01 to about 5 IU/lb./day such that the interferon is held in contact with the patient's oral and ...